Lumizyme (alglucosidase alfa) (Intravenous)
Customize your policy alerts
Sign up for Moda Health Policy M-0079 alerts
Get alerted when Policy M-0079 changes without checking for updates manually.
Monitor payer policy activity
Defines Moda Health prior authorization, dosing limits, medical necessity criteria, renewal conditions, and billing codes for intravenous Lumizyme (alglucosidase alfa) for treatment of Pompe disease.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.